CML-466 Asciminib Provides Durable Molecular Responses in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With the T315I Mutation: Updated Efficacy and Safety Data From a Phase I Trial.
暂无分享，去创建一个
M. Talpaz | M. Mauro | A. Hochhaus | T. Hughes | M. Breccia | F. Polydoros | S. Kapoor | P. le Coutre | F. Lang | D. Réa | K. Sasaki | Y. Goh | Jordi Cortés | N. Agrawal | F. Mahon | J. Janssen | D. Kim | M. Deininger | S. Cacciatore | V. Gómez García de Soria | M. Heinrich